Active, not recruitingPhase 1NCT02483312

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Hassan Sibai, M.D.
Princess Margaret Cancer Centre
Intervention
IL-12(biological)
Enrollment
9 enrolled
Eligibility
18 years · All sexes
Timeline
20152026

Study locations (1)

Collaborators

Ozmosis Research Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02483312 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials